Literature DB >> 6176999

Effect of a conjugate of daunomycin and antibodies to rat alpha-fetoprotein on the growth of alpha-fetoprotein-producing tumor cells.

Y Tsukada, W K Bischof, N Hibi, H Hirai, E Hurwitz, M Sela.   

Abstract

Daunomycin was covalently attached via a dextran bridge to specific antibodies against rat alpha-fetoprotein produced in a horse. The effect of this conjugate on an alpha-fetoprotein-producing tumor was investigated in terms of cytotoxicity and inhibition or retardation of tumor development. Under the experimental conditions used, the covalent conjugate was by both criteria more efficient than either daunomycin alone or a mixture of daunomycin and specific antibodies or a conjugate of daunomycin with horse immunoglobulin. These results show that the conjugate may be useful as a specific cytotoxic agent against alpha-fetoprotein-producing tumors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6176999      PMCID: PMC345798          DOI: 10.1073/pnas.79.2.621

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Normal distribution, patching and capping of lymphocyte surface immunoglobulin studied by electron microscopy.

Authors:  S de Petris; M C Raff
Journal:  Nat New Biol       Date:  1973-02-28

2.  Purification of human, dog and rabbit -fetoprotein by immunoadsorbents of sepharose coupled with anti-human -fetoprotein.

Authors:  S Nishi; H Hirai
Journal:  Biochim Biophys Acta       Date:  1972-09-29

3.  Effect of anti-alpha-fetoprotein serum on some cultured tumor cells.

Authors:  Y Tsukada; M Mikuni; H Watabe; S Nishi; H Hirai
Journal:  Int J Cancer       Date:  1974-02-15       Impact factor: 7.396

4.  In vitro cloning of a rat ascites hepatoma cell line, AH66, with special reference to alpha-fetoprotein synthesis.

Authors:  Y Tsukada; M Mikuni; H Hirai
Journal:  Int J Cancer       Date:  1974-02-15       Impact factor: 7.396

5.  Immunotherapeutic suppression in transplantable solid tumours.

Authors:  G J Mizejewski; R P Allen
Journal:  Nature       Date:  1974-07-05       Impact factor: 49.962

6.  A new and simple radioimmunoassay method for the determination of IgE.

Authors:  M Ceska; U Lundkvist
Journal:  Immunochemistry       Date:  1972-10

7.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

8.  Different biding sites in DNA for actinomycin and daunomycin.

Authors:  A Rusconi
Journal:  Biochim Biophys Acta       Date:  1966-09

9.  Isolation and characterization of a human fetal-alpha-globulin from the sera of fetuses and a hepatoma patient.

Authors:  S Nishi
Journal:  Cancer Res       Date:  1970-10       Impact factor: 12.701

10.  Plasma membrane and internalized immunoglobulins of lymph node cells studied with conjugates of antibody or its Fab fragments with horseradish peroxidase.

Authors:  J C Antoine; S Avrameas; N K Gonatas; A Stieber; J O Gonatas
Journal:  J Cell Biol       Date:  1974-10       Impact factor: 10.539

View more
  17 in total

1.  Evaluation of a conjugate of purified antibodies against human AFP-dextran-daunorubicin to human AFP-producing yolk sac tumor cell lines.

Authors:  K Ohkawa; N Hibi; Y Tsukada
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Selective cytotoxicity against tumor cells by cisplatin complexed to antitumor antibodies via carboxymethyl dextran.

Authors:  B Schechter; R Pauzner; R Arnon; J Haimovich; M Wilchek
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor.

Authors:  E Aboud-Pirak; E Hurwitz; F Bellot; J Schlessinger; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

4.  Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue.

Authors:  E Lavie; D L Hirschberg; G Schreiber; K Thor; L Hill; I Hellstrom; K E Hellstrom
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Doxorubicin conjugates of monoclonal antibodies to hepatoma-associated antigens.

Authors:  D Shouval; R Adler; J R Wands; E Hurwitz; K J Isselbacher; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

6.  Inhibition of Epstein-Barr-virus-transformed human chronic lymphocytic leukaemic B cells with monoclonal-antibody-adriamycin (doxorubicin) conjugates.

Authors:  Z Zhu; J Kralovec; T Ghose; M Mammen
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

7.  Ricin A-chain conjugated with monoclonal anti-L1210 antibody. In vitro and in vivo antitumor activity.

Authors:  K Kishida; Y Masuho; M Saito; T Hara; H Fuji
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

8.  Selective killing of smooth muscle cells in culture by the ricin A-chain conjugated with monoclonal antibodies to a cell surface antigen via a dextran bridge.

Authors:  A I Faerman; A V Maksimenko; A G Tonevitsky; O B Ilynsky; V P Torchilin
Journal:  Experientia       Date:  1985-10-15

9.  Chemotherapy by intravenous administration of conjugates of daunomycin with monoclonal and conventional anti-rat alpha-fetoprotein antibodies.

Authors:  Y Tsukada; E Hurwitz; R Kashi; M Sela; N Hibi; A Hara; H Hirai
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

10.  Selective in vitro and in vivo growth inhibition against human yolk sac tumor cell lines by purified antibody against human alpha-fetoprotein conjugated with mitomycin C via human serum albumin.

Authors:  K Ohkawa; Y Tsukada; N Hibi; N Umemoto; T Hara
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.